83,654 Shares in Pfizer Inc. (NYSE:PFE) Bought by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 83,654 shares of the biopharmaceutical company's stock, valued at approximately $2,219,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $28,000. Finally, Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE traded up $0.23 during mid-day trading on Friday, reaching $22.83. 37,727,922 shares of the company were exchanged, compared to its average volume of 40,866,555. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $129.77 billion, a PE ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a fifty day moving average of $23.72 and a 200 day moving average of $25.40.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's payout ratio is presently 124.64%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.